mpc-3100
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2009 (NCT00920205)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
HSP90AB2P inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 1-(4-(2-(6-amino-8-((6-bromo-1,3-benzodioxol-5-yl)sulfanyl)-9h-purin-9-yl)ethyl)piperidin-1-yl)-2-hydroxypropan-1-one
- mpc-3100
- mpc-3100
- mpc-3100
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00920205 | Phase 1 | Jun 1, 2009 | Myrexis Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Myrexis Inc. | For profit | 1 | 1 | 1 | 2009 |
1 organizations
Page 1 / 1